Spatial transcriptomic validation of a biomimetic model of fibrosis enables re-evaluation of a therapeutic antibody targeting LOXL2.
Bell JA, Davies ER, Brereton CJ, Vukmirovic M, Roberts JJW, Lunn K, Wickens L, Conforti F, Ridley RA, Ceccato J, Sayer LN, Johnston DA, Vallejo AF, Alzetani A, Jogai S, Marshall BG, Fabre A, Richeldi L, Monk PD, Skipp P, Kaminski N, Offer E, Wang Y, Davies DE, Jones MG.
Bell JA, et al. Among authors: richeldi l.
Cell Rep Med. 2024 Sep 17;5(9):101695. doi: 10.1016/j.xcrm.2024.101695. Epub 2024 Aug 21.
Cell Rep Med. 2024.
PMID: 39173635
Free PMC article.